- 39
- 84 661
INmune Bio - The Innate Immune Company
United States
Приєднався 27 лют 2017
We focus on topics about the innate immune system's role in disease. Please refer to our risk factors and forward looking statements found on our web site or SEC filings. Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements by INmune Bio that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements.
Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer’s Trials
This video explores the development of EMACC and its advantages in assessing cognitive changes over time in early Alzheimer’s Disease (AD) patients. It will also cover the regulatory landscape for Alzheimer’s disease drug development and the role of the CDR-SB clinical scale. Speakers include Dr. Judith Jaeger, President of CognitionMetrics and leader of the team that developed and validated EMACC, Dr. Sarah Barnum, and CJ Barnum, VP of CNS Drug Development at INmune Bio.
EMACC has incredible potential to improve AD clinical development by improving assessment of cognitive changes. This will lead to smaller, shorter clinical trials, which means less burden on both patients and investors in terms of time and money.
#alzheimer #podcast #interview #alzheimersdisease #alzheimersresearch #clinical #neuromedicine #neuroscience #cognitivedecline #cognition #xpro1595 #inmune #clinicaltrial #clinicaltrials #biotechnology #biotech #biotechinnovation
EMACC has incredible potential to improve AD clinical development by improving assessment of cognitive changes. This will lead to smaller, shorter clinical trials, which means less burden on both patients and investors in terms of time and money.
#alzheimer #podcast #interview #alzheimersdisease #alzheimersresearch #clinical #neuromedicine #neuroscience #cognitivedecline #cognition #xpro1595 #inmune #clinicaltrial #clinicaltrials #biotechnology #biotech #biotechinnovation
Переглядів: 79
Відео
INside INmune Bio Vol 7
Переглядів 24021 день тому
Data from Animal Model Study Demonstrate XPro™ converts microglia from a demyelinating cell to a remyelinating cell. The study, Microglia Regulate Cortical Remyelination via ΤNFR1-Dependent Phenotypic Polarization published in Cell Reports has implications for many CNS diseases including Alzheimer’s. In Volume 7, Parris Pope speaks to the importance of this publication. www.cell.com/cell-report...
Inside INmune Bio Volume 6 - EMACC and CDR-SB
Переглядів 4442 місяці тому
INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, today announced that results of additional analysis of blinded data from its AD02 Phase II Alzheimer's Disease (AD) trial demonstrated exceptional performance of the novel cognitive measure EMACC, as well as highly significant correlation between EMACC and the Clinical Dementia Rating-Sum of Bo...
Inside INmune Bio Volume 5 - Memory Like NK Cells
Переглядів 3373 місяці тому
Professor Mark Lowdell offers an in-depth exploration of Natural Killer (NK) cells, focusing on their crucial role in tumor cell surveillance, as well as their dysfunction and activation. He also delves into the significance of memory-like NK cells and their potential impact on immunotherapy. #immunotherapy #nkcell #inkmune #inmunebio #cancer #cancerresearch #cytokines
XPro1595 Patient Experience
Переглядів 6696 місяців тому
This 63 year old male with Early Alzheimer’s Disease who participated in the open label Phase I trial in Alzheimer’s disease with biomarkers of inflammation. The patient was part of the of the 1mg/kg/week dose cohort. The patient chose to enroll in the open label extension after he completed the 3 month Phase I trial. After completion of the 12-month open label extension, his physician requeste...
INside INmune Bio | Episode 4 - Biomarkers
Переглядів 254Рік тому
In this episode, David Moss and RJ Tesi discuss biomarkers of neuroinflammation and their use in clinical development of XPro1595. INside INmune Bio is a video series directed to the inner workings of INmune Bio. Follow us as we interview employees, collaborators and others in the biotechnology industry to share what we believe might be valuable information for people interested in biologic dru...
INside INmune Bio | Episode 3 - The Program in One Slide
Переглядів 255Рік тому
In this episode, David Moss discusses each of INmune Bio's clinical programs in a brief single-slide format. INside INmune Bio is a video series directed to the inner workings of INmune Bio. Follow us as we interview employees, collaborators and others in the biotechnology industry to share what we believe might be valuable information for people interested in biologic drug development. We inte...
INside INmune Bio | Episode 2 - TNF "the master cytokine"
Переглядів 365Рік тому
INside INmune Bio is a video series directed to the inner workings of INmune Bio. Follow us as we interview employees, collaborators and others in the biotechnology industry to share what we believe might be valuable information for people interested in biologic drug development. We intend to upload at least once monthly and whenever opportunities present themselves. Suggest topics or leave que...
INside INmune Bio - inaugural interview with Joshua Schoonover, General Counsel.
Переглядів 281Рік тому
INside INmune Bio is a video series directed to the inner workings of INmune Bio. Follow us as we interview employees, collaborators and others in the biotechnology industry to share what we believe might be valuable information for people interested in biologic drug development. We intend to upload at least once monthly and whenever opportunities present themselves. Suggest topics or leave que...
Webinar on INKmune, a Natural Killer Therapy for a Phase I/II Trial in Metastatic Prostate Cancer
Переглядів 251Рік тому
Webinar to discuss INKmune™ in a phase I/II clinical trial for the treatment of men with mCRPC and provide details of the clinical trial design. RJ. Tesi, MD, will moderate a discussion between Prof. Matt Rettig, MD and Prof. Mark Lowdell, PhD. #cancer #prostatecancer #INKmune #biotechnology #biology
DNTNF_moa
Переглядів 425Рік тому
Dominant Negative TNF (DN-TNF) is a novel biologic designed to disrupt soluble TNF trimers and insert itself into a newly formed heterotrimer containing at least one DN-TNF monomer and up to two solTNF monomer(s). The DN-TNF solTNF heterotrimer does not bind TNFR. As such, DN-TNF effectively neutralizes solTNF, thereby attenuating inflammation.
Prof. Mark Lowdell Explains How INKmune Arms Natural Killer Cells to Kill Solid Tumors
Переглядів 5752 роки тому
Dr. Mark Lowdell, CSO of INmune Bio gave a plenary talk on October 17, 2022 at the Innate Killer Summit, London to explain how INKmune arms Natural Killer (NK) to override immunosuppression in an active Tumor Microenvironment (TME) to kill solid tumors. The interaction of the TME with cancer cells and immune cells can drive tumor progression and prevent many cell therapies from being effective....
INmune Bio Phase 2 Clinical Trial of Xpro in Alzheimer's Disease
Переглядів 4092 роки тому
In this video Dr. CJ Barnum provides an overview of our two clinical trials in Alzheimer's Disease. One in mild AD and the other in Mild Cognitive Impairment (MCI). #alzheimer #dementia #xpro1595 #neuroinflammation #neurology #neuroscience #cns #alzheimersdisease #alzheimers
Viewing Alzheimer's as an Immunological Disease with Symptoms of Neurodegeneration
Переглядів 1812 роки тому
In this video Dr. CJ Barnum describes INmune's approach to Alzheimer's and neurologic disease as an immunologic disease with symptoms of neurodegeneration versus the scientific community that views Alzheimer's as a neurological disease with side effects of immune dysfunction. #alzheimer #neuroinflammation #neuroscience #neurology #cns #immunology #neurodegeneration #xpro1595
The INmune Bio Approach to Alzheimer's Disease
Переглядів 5392 роки тому
In this video Dr. CJ Barnum describes how INmune Bio differs than other biotechnology companies in the way we approach Alzheimer's Disease.
How XPro1595 ("XPro") is Unique to Other TNF Inhibitors
Переглядів 1682 роки тому
How XPro1595 ("XPro") is Unique to Other TNF Inhibitors
Targeting Neuroinflammation in Alzheimer's Disease
Переглядів 5282 роки тому
Targeting Neuroinflammation in Alzheimer's Disease
Beneficial microglia responses drive remyelination through inhibition of sTNF in grey matter.
Переглядів 6912 роки тому
Beneficial microglia responses drive remyelination through inhibition of sTNF in grey matter.
Webinar on Results of XPro in AD Showing Improvements in White Matter Pathology and Decrease in PTau
Переглядів 1,1 тис.3 роки тому
Webinar on Results of XPro in AD Showing Improvements in White Matter Pathology and Decrease in PTau
Introduction to NK Cell Immunotherapy with INKmune - Priming NK Cells
Переглядів 47 тис.3 роки тому
Introduction to NK Cell Immunotherapy with INKmune - Priming NK Cells
XPro1595 Webinar on Expanded Phase 1b Data in Patients with Alzheimer’s Disease
Переглядів 1,3 тис.3 роки тому
XPro1595 Webinar on Expanded Phase 1b Data in Patients with Alzheimer’s Disease
XPro1595 and Treatment Resistant Depression (TRD) KOL Event
Переглядів 9664 роки тому
XPro1595 and Treatment Resistant Depression (TRD) KOL Event
Webinar on XPro1595 Phase Ib Interim Data of Neuroinflammation in Patients with Alzheimer's Disease
Переглядів 1,7 тис.4 роки тому
Webinar on XPro1595 Phase Ib Interim Data of Neuroinflammation in Patients with Alzheimer's Disease
INB03 and Lapatinib Reverses Resistance to Trastuzumab in HER2+ Breat Cancer in Pre-clinical Models.
Переглядів 3714 роки тому
INB03 and Lapatinib Reverses Resistance to Trastuzumab in HER2 Breat Cancer in Pre-clinical Models.
INKmune vs. Resting NK cells vs. IL-15 NK cells.
Переглядів 15 тис.4 роки тому
INKmune vs. Resting NK cells vs. IL-15 NK cells.
Bench to Bedside A Pre CTAD Webinar Highlighting An Alternative Approach For Alzheimer’s Disease
Переглядів 2744 роки тому
Bench to Bedside A Pre CTAD Webinar Highlighting An Alternative Approach For Alzheimer’s Disease
INmune Bio's RJ Tesi and University of Florida's Malu Tansey Cutting Edge Podcast
Переглядів 1085 років тому
INmune Bio's RJ Tesi and University of Florida's Malu Tansey Cutting Edge Podcast
How do you Test NK cytotoxic cells?
Do you have a protocol to remove all those “dead” garbage cells after treatment?
TNFR2 is important for maintaining brain function.
It is important to keep TNFR2 intact. Maybe TNFR2 agonist can help.
Very nice! Always enjoys listening and learning from you.
Great podcast. I have heard some of this before directly from David and it is indeed fascinating and revolutionary. I hope you guys are able to help a great number of people. Btw, I could also really use a hat to go with my INmune pen 😉
good info like the fact you have looked at trying to measure success in multiple different ways. what if anything did you learn from the 3 other companies and their scans/tests/biomarkers?
It will be great to know how Xpro and INkmune will be manufactured when they are commercialized.
Great presentation! It is a common sense to look at the degree of the disease using bio marker. We have been using it for many diseases like cancer. It is a great way to look at the CNS diseases especially when the disease symptoms are difficult to measure using conventional methods.
Great guys, one of your investors and would like a hat as well
Just know about Inside INmune. As an investor it is Great to know that our innovative bio products have 12 years of exclusivity by FDA.
"Promosm" ✌️
How is your xPro different than recently PH2 FDA approved trial for Tiziana AD drug? They seem to be targeting neuro inflammation as well. They expect PH2 results 4th quarter of 2024.
We do not comment on other company approaches but we know that TNF is the master cytokine of the inflammatory cascade. The entire TNF drug franchise, arguably the best selling drug franchise in the world has treated many millions of patients with billions of doses. We also know that rheumatoid arthritis patients that take TNF inhibitors have a much lower incidence of Alzheimer's compared to the normal population. That only worked by treating with a TNF inhibitor, not another anti-inflammatory. So why target something else, or be downstream? I encourage you to google, "TNF inhibitors and Alzheimer's" Note: our drug is experimental and is currently in clinical trials and is not approved by any regulatory agency, nor may ever be. I encourage you to read our forward looking statements.
Excellent compendium of INMB’s programs and where they are in progress of drug and where they are going!
Nice one slide descriptions of programs!
This video really helped my understanding of TNF
Nice episode! Love the tech and hoping for your success here...
Here for the hat to where on an “end AD” walk
When is the walk and where? Link your walk details and we will support.
I see enormous PR opportunities exploring treatment potential for CTE. Billions are at stake for contact sports that have no treatment options for retired players that are suffering.
We have done work in TBI. Feel free to google XPro1595 and TBI.
If XPro does all the good stated and is safe, then why the FDA hold? Why not get it to market immediately and help thousands? Not sensible
The hold is due to changing the manufacturing facility where XPRO is produce. Out of their control the FDA is full of lazy and incompetent government employees.
The FDA hold is all around manufacturing which we are addressing. The process to get a drug approved requires clinical trials which is the barrier to entry for everyone developing pharmaceuticals.
That is one good looking hat!
Very informative
Great format and super informative.
Nicely done! As a shareholder I appreciate the effort and the information shared here - and I did learn some new stuff. Keep it up!
Thank you for your feedback -- expect more.